Erika Hamilton

Nov 18, 2024 | oncologynewscentral.com | Rohit Gosain |Rahul Gosain |Erika Hamilton |Tian Zhang

Rahul Gosain: Hello, and welcome back to another episode of the Oncology Brothers. I’m Rahul Gosain, here with my brother and co-host, Rohit Gosain. Today, we’re kicking off a new series focusing, not just on drug approvals, but rather, on managing side effects of approved agents in our community settings. Rahit Gosain: Rahul, you’re right. It’s not just about knowing these approvals, but rather to get comfortable in managing some of these side effects.

Aug 10, 2024 | cancernetwork.com | Erika Hamilton |Rinath Jeselsohn |Sara A. Hurvitz |Dejan Juric |Hyo S Han |Melinda L. Telli | +8 more

BackgroundVepdegestrant (ARV-471) is an oral proteolysis-targeting chimeras (PROTAC) estrogen receptor (ER) degrader. In a phase 1/2 study (NCT04072952), vepdegestrant monotherapy had a favorable safety profile and encouraging clinical activity with robust ER degradation. The phase 1b cohort of this study is evaluating vepdegestrant plus the CDK4/6inhibitor palbociclib.

Aug 4, 2024 | cancernetwork.com | Sara A. Hurvitz |Anne F. Schott |Cynthia X. MA |Rita Nanda |George Zahrah |Natasha Hunter | +10 more

BackgroundVepdegestrant (ARV-471) is an oral proteolysis-targeting chimeric (PROTAC) estrogen receptor (ER) degrader with activity toward wild-type and mutant ER. The phase 2 expansion (VERITAC) of a phase 1/2 study tested 2 vepdegestrant doses (200 mg once daily and 500 mg once daily) in heavily pretreated patients with ER+/HER2-negative (HER2–) advanced breast cancer.

Jul 21, 2024 | cancernetwork.com | Hope Rugo |Aditya Bardia |Erika Hamilton |Sara A. Hurvitz |Sara M. Tolaney |Virginia Kaklamani | +3 more

BackgroundEndocrine therapy (ET) plus CDK4/6 inhibitor is the mainstay for the management of estrogen receptor-positive (ER+)/HER2- negative (HER2–) metastatic breast cancer (mBC) as first-line therapy; however, tumors eventually develop resistance to ET. After progression on first-line ET plus CDK4/6 inhibitors, both ET monotherapy and combination therapies are available.

Jun 24, 2024 | nature.com | Yeon Hee Park |David Sommerhalder |Kan Yonemori |Erika Hamilton |Toshinari Yamashita |Rachel M. Layman | +3 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03060-0, published online 1 June 2024In the version of the article initially published, in Extended Data Fig. 1, under “Part 1B”, “5 mg QD” originally read “3 dose levels” and “n=9” was missing from that box. There was originally an additional “Cohort 1 (5 mg QD, n=9)” box that has now been removed. Under “Part “2A”, the text “fulvestrant 500 mg” originally preceded “(n=35)”. In Extended Data Fig.